3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Carcinoma, Hepatocellular
1
Interventions
Rituximab
23
Cyclophosphamide
11
Radiotherapy
8
Prednisone
8
Vincristine
7
Doxorubicin
7
Lenalidomide
6
Bendamustine Hydrochloride
5
Chlorambucil
4
Peripheral Blood Stem Cell Transplantation
3
Filgrastim
3
obinutuzumab
2
liposomal amphotericin B
2
idelalisib
2
ibrutinib
2
fludarabine phosphate
2
VAP-cyclo protocol
2
Therapeutics
2
Psychiatric Rehabilitation
2
Levofloxacin
2
Interferon-alpha
2
Idarubicin
2
Epoetin Alfa
2
Early Intervention, Educational
2
Cyclosporine
2
Busulfan
2
zanubrutinib
1
tafasitamab
1
parsaclisib
1
orelabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell, Marginal Zone
×
Fluorodeoxyglucose F18
×
Clear all
NCT06125028
2026-04-28
LYMFOR
Pentixapharm AG
Phase 3
Terminated
8 enrolled